» Articles » PMID: 30116541

Development of a Model to Predict 5-year Risk of Severe Hypoglycemia in Patients with Type 2 Diabetes

Overview
Specialty Endocrinology
Date 2018 Aug 18
PMID 30116541
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We constructed a predictive model of long-term risk for severe hypoglycemia (SH: hypoglycemia requiring assistance) in patients with type 2 diabetes (T2DM).

Research Design And Methods: Data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (original n=10 251, n=5135 used in the current analysis), a randomized, multicenter, double 2×2 factorial design study examining the effect of glycemic, blood pressure, and lipid control on cardiovascular outcomes in patients with diagnosed T2DM, were used. Over the follow-up (3.76±1.12 years), the ACCORD participants experienced 607 incident SH events. Cox regression was used to identify the SH risk prediction model.

Results: We identified 17 predictors-glycemic management, age, race, education, waist circumference, medications (insulin, antihypertensive, HMG-CoA reductase inhibitors, sulfonylurea, biguanide and meglitinide), years since diabetes diagnosis, history of hypoglycemia in the last week, systolic blood pressure, diastolic blood pressure, serum creatinine, and urinary albumin creatinine ratio-to construct a prediction model for SH (c-statistic=0.782). Using this information, we derived point scores to estimate the 5-year risk for SH in individual patients with T2DM. After adjusting for other variables in the model, the three strongest predictors for SH over 5 years were intensive glycemic management (HR=2.37, 95% CI 1.99 to 2.83), insulin use (HR=2.14, 95% CI 1.77 to 2.59), and antihypertensive medication use (HR=1.90, 95% CI 1.26 to 2.86).

Conclusion: Using the ACCORD data, we identified attributes to predict 5-year risk of SH in patients with T2DM, which warrant evaluation in broader populations to determine applicability.

Citing Articles

6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S128-S145.

PMID: 39651981 PMC: 11635034. DOI: 10.2337/dc25-S006.


Artificial Intelligence to Diagnose Complications of Diabetes.

Ayers A, Ho C, Kerr D, Cichosz S, Mathioudakis N, Wang M J Diabetes Sci Technol. 2024; 19(1):246-264.

PMID: 39578435 PMC: 11688687. DOI: 10.1177/19322968241287773.


Screening for Hypoglycaemia Risk and Medication Changes in Diabetes Patients Using Pharmacy Dispensing Data.

Cahyaningsih I, Asiri A, de Vos S, Bos J, Schuiling-Veninga C, Taxis K J Clin Med. 2024; 13(19).

PMID: 39407915 PMC: 11477424. DOI: 10.3390/jcm13195855.


A novel electronic health record-based, machine-learning model to predict severe hypoglycemia leading to hospitalizations in older adults with diabetes: A territory-wide cohort and modeling study.

Shi M, Yang A, Lau E, Luk A, Ma R, Kong A PLoS Med. 2024; 21(4):e1004369.

PMID: 38607977 PMC: 11014435. DOI: 10.1371/journal.pmed.1004369.


Development and validation of a prediction model for self-reported hypoglycemia risk in patients with type 2 diabetes: A longitudinal cohort study.

Xu H, Yu H, Cheng Z, Mu C, Bao D, Li X J Diabetes Investig. 2024; 15(4):468-482.

PMID: 38243656 PMC: 10981142. DOI: 10.1111/jdi.14135.


References
1.
Gerstein H, Miller M, Ismail-Beigi F, Largay J, McDonald C, Lochnan H . Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014; 384(9958):1936-41. PMC: 4397008. DOI: 10.1016/S0140-6736(14)60611-5. View

2.
Marrett E, Radican L, Davies M, Zhang Q . Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes. 2011; 4:251. PMC: 3148563. DOI: 10.1186/1756-0500-4-251. View

3.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

4.
Miller M, Bonds D, Gerstein H, Seaquist E, Bergenstal R, Calles-Escandon J . The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b5444. PMC: 2803743. DOI: 10.1136/bmj.b5444. View

5.
Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View